Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.

Sekeres MA, Gundacker H, Lancet J, Advani A, Petersdorf S, Liesveld J, Mulford D, Norwood T, Willman CL, Appelbaum FR, List AF.

Blood. 2011 Jul 21;118(3):523-8. doi: 10.1182/blood-2011-02-337303. Epub 2011 May 6.

2.

Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.

Giagounidis AA.

Semin Hematol. 2012 Oct;49(4):312-22. doi: 10.1053/j.seminhematol.2012.07.001. Review.

PMID:
23079061
3.

Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.

List A.

Clin Lymphoma Myeloma. 2009;9 Suppl 3:S302-4. doi: 10.3816/CLM.2009.s.028. Review.

PMID:
19778857
4.

Role of lenalidomide in the treatment of myelodysplastic syndromes.

Komrokji RS, List AF.

Semin Oncol. 2011 Oct;38(5):648-57. doi: 10.1053/j.seminoncol.2011.04.015. Review.

PMID:
21943671
6.

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.

Giagounidis A, Mufti GJ, Fenaux P, Germing U, List A, MacBeth KJ.

Ann Hematol. 2014 Jan;93(1):1-11. doi: 10.1007/s00277-013-1863-5. Epub 2013 Sep 10. Review.

7.

Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.

Gaballa MR, Besa EC.

Ann Hematol. 2014 May;93(5):723-33. doi: 10.1007/s00277-014-2022-3. Epub 2014 Mar 14. Review.

PMID:
24627193
8.

The role of lenalidomide in the management of myelodysplasia with del 5q.

Kelaidi C, Eclache V, Fenaux P.

Br J Haematol. 2008 Feb;140(3):267-78. doi: 10.1111/j.1365-2141.2007.06910.x. Review.

PMID:
18217896
9.

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.

Komrokji RS, List AF.

Ann Oncol. 2016 Jan;27(1):62-8. doi: 10.1093/annonc/mdv488. Epub 2015 Oct 26. Review.

10.

Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.

Heise C, Carter T, Schafer P, Chopra R.

Expert Rev Anticancer Ther. 2010 Oct;10(10):1663-72. doi: 10.1586/era.10.135. Review.

PMID:
20942636
11.

Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.

List AF, Baker AF, Green S, Bellamy W.

Cancer Control. 2006 Dec;13 Suppl:4-11. Review.

12.

Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies.

Giagounidis AA, Germing U, Aul C.

Clin Cancer Res. 2006 Jan 1;12(1):5-10. Review.

13.

Where Does Lenalidomide Fit in Non-del(5q) MDS?

Giagounidis A.

Curr Hematol Malig Rep. 2015 Sep;10(3):303-8. doi: 10.1007/s11899-015-0275-0. Review.

PMID:
26169489
14.

Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.

Komrokji RS, List AF.

Hematol Oncol Clin North Am. 2010 Apr;24(2):377-88. doi: 10.1016/j.hoc.2010.02.013. Review.

PMID:
20359632
15.

Treatment of the 5q- syndrome.

Fenaux P, Kelaidi C.

Hematology Am Soc Hematol Educ Program. 2006:192-8. Review.

PMID:
17124060
16.
17.

New complex t(2;11;17)(p21;q23;q11), a variant form of t(2;11), associated with del(5)(q23q32) in myelodysplastic syndrome-derived acute myeloblastic leukemia.

Yamamoto K, Nagata K, Morita Y, Inagaki K, Hamaguchi H.

Cancer Genet Cytogenet. 2002 Sep;137(2):119-23. Review.

PMID:
12393282
18.

PP2A: The Achilles Heal in MDS with 5q Deletion.

Sallman DA, Wei S, List A.

Front Oncol. 2014 Sep 23;4:264. doi: 10.3389/fonc.2014.00264. eCollection 2014. Review.

Supplemental Content

Support Center